<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840539</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-1602-153-747</org_study_id>
    <nct_id>NCT02840539</nct_id>
  </id_info>
  <brief_title>Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma</brief_title>
  <acronym>BATMAN</acronym>
  <official_title>A Phase 2 Trial to Evaluate the Efficacy of Bortezomib, Cytarabine, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consortium for Improving Survival of Lymphoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone
      are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3
      lines of previous treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response</measure>
    <time_frame>within 28 days after the last cycle of treatment</time_frame>
    <description>Lugano classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>within 28 days after the last cycle of treatment</time_frame>
    <description>Lugano classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Interval from registration to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Interval from registration to progression or death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>within 28 days after the last cycle of treatment</time_frame>
    <description>EORTC QLQ-C30</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>within 28 days after the last cycle of treatment</time_frame>
    <description>NCI CTCAE version 4.03</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib, Cytarabine, Dexamethasone, Pegteograstim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, Cytarabine, Dexamethasone, Pegteograstim</intervention_name>
    <description>Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle
Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older
Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle
Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Protezomib, Cytarabine, Dexamethasone, Neulapeg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed mantle cell lymphoma

          -  Relapse or progression after 1-3 lines of previous chemotherapy with or without
             immunologic agents

          -  ECOG performance status 2 or less

          -  Adequate hematologic, hepatic, and renal function i. White blood cells ≥ 3,000 /ul ii.
             Absolute neutrophil count ≥ 1,000 /ul iii. Platelets ≥ 50,000 /ul iv. Hemoglobin ≥ 9.0
             g/dL v. Total bilirubin &lt; 2 times upper limit of normal vi. AST, ALT &lt; 2.5 times upper
             limit of normal vii. Serum creatinine &lt; 1.5 times upper limit of normal

        Exclusion Criteria:

          -  Previously treated with 4 or more lines of chemotherapy with or without immunologic
             agents

          -  Previously treated with bortezomib

          -  Treated with a cytarabine-containing regimen as the last line and within 6 months
             before registration

          -  Other cancer diagnosed within 5 years before registration

          -  Uncontrolled symptomatic CNS involvement of mantle cell lymphoma

          -  Uncontrolled systemic infection

          -  Inherited immunodeficiency disease or AIDS

          -  Pregnancy

          -  Breast-feeding

          -  Peripheral neuropathy of grade 3 or higher

          -  Other health conditions considered to be inappropriate for this trial in the primary
             physician's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngil Koh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunhee Park, CRN</last_name>
    <phone>82-2-743-1453</phone>
    <email>eh.park@daum.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junghoon Shin, MD</last_name>
    <phone>82-10-2015-4932</phone>
    <email>freeustand@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunhee Park, CRN</last_name>
      <phone>82-2-743-1453</phone>
      <email>eh.park@daum.net</email>
    </contact>
    <investigator>
      <last_name>Junghoon Shin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.</citation>
    <PMID>25738670</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Youngil Koh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Cytarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Demographics, baseline characteristics, response, survival data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

